• Ivan Urits, Melis Yilmaz, Ehab Bahrun, Caitlin Merley, Logan Scoon, Grace Lassiter, Daniel An, Vwaire Orhurhu, Alan D Kaye, and Omar Viswanath.
• Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: ivanurits@gmail.com.
• Best Pract Res Clin Anaesthesiol. 2020 Sep 1; 34 (3): 479-491.

AbstractChronic migraine is a particular classification of a headache that is typically unilateral and pulsatile and lasts for at least 3 months. Owing to its high prevalence and detrimental impact on personal, social, and economic aspects of patient lives, much desire has gone into fully understanding the pathogenesis of migraine, and to search for therapeutic agents. In addition to current therapeutics such as triptans, ergotamine, and monoclonal antibodies targeting calcitonin gene-related peptide receptors, vitamin B12 has been investigated for its possible use as a prophylactic agent for migraines. Specifically, the observed effects of vitamin B12 on nitric oxide and homocysteine prompt further investigation of its underlying mechanisms in migraine pathophysiology. In this comprehensive review, we provide a brief overview of migraines and current therapies while focusing on the promising role of vitamin B12 as a possible treatment option for chronic migraine management.Copyright © 2020. Published by Elsevier Ltd.

31 keywords...

hide…